Lyndsey N. Runaas

Lyndsey N. Runaas

Hematology | Oncology
1626 Tuttle St.
Baraboo, WI 53913

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 36 publications

Differential effects of two common GVHD prophylaxis regimens on the gut microbiome: Results from the BMT CTN 1801 study.

Differential effects of two common GVHD prophylaxis regimens on the gut microbiome: Results from the BMT CTN 1801 study.

Journal: bioRxiv : the preprint server for biology
Published: February 27, 2026

TIDRAKIZUMAB FOR THE PROPHYLAXIS OF GRAFT VERSUS HOST DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION.

TIDRAKIZUMAB FOR THE PROPHYLAXIS OF GRAFT VERSUS HOST DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION.

Journal: Blood advances
Published: November 12, 2025

Tildrakizumab for the prophylaxis of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.

Tildrakizumab for the prophylaxis of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.

Journal: Blood advances
Published: November 12, 2025

Visualizing Health Related Quality of Life (HRQoL): understanding comprehension of HRQoL graphs in the allogeneic hematopoietic cell transplant setting.

Visualizing Health Related Quality of Life (HRQoL): understanding comprehension of HRQoL graphs in the allogeneic hematopoietic cell transplant setting.

Journal: Journal of cancer survivorship : research and practice
Published: September 24, 2025

CHARM is Prognostic of Geriatric Morbidity and Toxicity after Allogeneic Transplant for Older Adults: BMT CTN 1704 Study.

CHARM is Prognostic of Geriatric Morbidity and Toxicity after Allogeneic Transplant for Older Adults: BMT CTN 1704 Study.

Journal: Blood advances
Published: September 08, 2025

CHARM is prognostic of geriatric morbidity and toxicity after allogeneic transplant for older adults: BMT CTN 1704 study.

CHARM is prognostic of geriatric morbidity and toxicity after allogeneic transplant for older adults: BMT CTN 1704 study.

Journal: Blood advances
Published: September 08, 2025

Graft-versus-host disease prophylaxis shapes T cell biology and immune reconstitution after hematopoietic cell transplant.

Graft-versus-host disease prophylaxis shapes T cell biology and immune reconstitution after hematopoietic cell transplant.

Journal: medRxiv : the preprint server for health sciences
Published: March 10, 2025

Impact of posttransplant cyclophosphamide-based GVHD prophylaxis in patients 70 years and older: an update from BMT CTN 1703.

Impact of posttransplant cyclophosphamide-based GVHD prophylaxis in patients 70 years and older: an update from BMT CTN 1703.

Journal: Blood advances
Published: January 21, 2025

Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide: A Quality-of-Life Evaluation and 2-Year Outcomes of BMT CTN 1703.

Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide: A Quality-of-Life Evaluation and 2-Year Outcomes of BMT CTN 1703.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 03, 2025

Novel composite health assessment risk model for older allogeneic transplant recipients: BMT-CTN 1704.

Novel composite health assessment risk model for older allogeneic transplant recipients: BMT-CTN 1704.

Journal: Blood advances
Published: January 02, 2025

Accurate prediction of absolute prokaryotic abundance from DNA concentration.

Accurate prediction of absolute prokaryotic abundance from DNA concentration.

Journal: Cell reports methods
Published: November 02, 2024

Phase 1 study of lintuzumab-Ac225 combined with CLAG-M salvage therapy in relapsed/refractory acute myeloid leukemia.

Phase 1 study of lintuzumab-Ac225 combined with CLAG-M salvage therapy in relapsed/refractory acute myeloid leukemia.

Journal: Leukemia
Published: October 31, 2024
Showing 1-12 of 36

Last Updated: 09/26/2026